OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind

Background: Dulaglutide (DU) was superior to placebo (PL) in reducing the incidence of Major Adverse Cardiovascular Events in the Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND Study) broad patient population. The safety of DU treatment is also of interest to health car...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Endocr Soc
Main Authors: Konig, Manige, Gerstein, Hertzel C, Lakshmanan, Mark C, Xavier, Denis, Atisso, Charles, Allen, Sheryl, Cushman, William C, Leiter, Lawrence A, Raubenheimer, Peter J, Franek, Edward M
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Diabetes Mellitus and Glucose Metabolism
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7207332/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.071
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados